We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Adamas Pharmaceuticals, Inc. (“Adamas” or the Company”) (NASDAQ: ADMS) in connection with the proposed acquisition of the Company by Supernus Pharmaceuticals, Inc. (“Supernus”) (NASDAQ: SUPN), via a tender offer.  Under the terms of the merger agreement, the Company’s shareholders will receive $8.10 per share in cash payable at closing, plus two non-tradable contingent value rights collectively worth up to $1.00 per share in cash, payable upon achieving certain net sales thresholds of the Company’s lead product, GOCOVRI, for each share of Adamas common stock that they hold.

WeissLaw LLP is investigating whether (i) Adamas’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $8.10 per-share offer price adequately compensates Adamas’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.  Notably, the merger consideration is below the $9.00 median price targets set by analysts following the Company and at least one analyst set a price target for the Company of $14 per share, $5.90 above the per-share merger consideration.